作者: Marcílio S.S. Cunha-Filho , Ramón Martínez-Pacheco , Mariana Landín
DOI: 10.1016/J.JPBA.2007.08.016
关键词: Fourier transform infrared spectroscopy 、 Differential scanning calorimetry 、 Infrared spectroscopy 、 Nuclear chemistry 、 Mannitol 、 Chemistry 、 Excipient 、 Stereochemistry 、 Magnesium stearate 、 Diluent 、 Dosage form
摘要: Abstract The objective of the present study was to evaluate compatibility β-lapachone (βLAP), an antitumoral drug in clinical phase, with pharmaceutical excipients common use including diluents, binders, disintegrants, lubricants and solubilising agents. Differential scanning calorimetry (DSC) used for a first screening find small variations peak temperatures and/or their associated enthalpy six drug/excipient combinations (magnesium stearate, sodium estearyl fumarate, dicalcium phosphate dihydrate, mannitol, randomized methyl-β-cyclodextrin hydroxypropyl-β-cyclodextrin), which indicate some degree interaction. Additional studies using Fourier transformed infrared spectroscopy (FTIR), optical microscopy (OM) heating–cooling DSC (HC-DSC) confirmed incompatibility βLAP magnesium stearate dihydrate. Those should be avoided development solid dosage forms.